Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001104659-25-020405
Filing Date
2025-03-04
Accepted
2025-03-04 17:08:04
Documents
13
Period of Report
2025-02-12
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 FORM 8-K/A tm258250d1_8ka.htm   iXBRL 8-K/A 27593
  Complete submission text file 0001104659-25-020405.txt   203099

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA mrkr-20250212.xsd EX-101.SCH 3018
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE mrkr-20250212_lab.xml EX-101.LAB 34240
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mrkr-20250212_pre.xml EX-101.PRE 22361
15 EXTRACTED XBRL INSTANCE DOCUMENT tm258250d1_8ka_htm.xml XML 3810
Mailing Address 2450 HOLCOMBE BLVD SUITE BCM-A, MS: BCM251 HOUSTON TX 77021
Business Address 2450 HOLCOMBE BLVD SUITE BCM-A, MS: BCM251 HOUSTON TX 77021 (713) 400-6400
Marker Therapeutics, Inc. (Filer) CIK: 0001094038 (see all company filings)

EIN.: 880277072 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-37939 | Film No.: 25706117
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)